MOFETYL 500 MG ( MYCOPHENOLATE MOFETIL ) 30 FILM-COATED TABLETS

Welcome visitor you can login or create an account.

Example

Returns

You can return the product within 14 days of purchase.

Returns

You can return the product within 14 days of purchase.

Description Reviews (0)

MOFETYL 500 MG ( MYCOPHENOLATE MOFETIL ) 30 FILM-COATED TABLETS

Mycophenolate mofetil (MMF) is a potent immunosuppressive agent and a prodrug of mycophenolic acid (MPA). It is primarily used to prevent organ rejection in transplant recipients and to manage various autoimmune conditions.

1. Mechanism of Action

MMF exerts its effects by selectively inhibiting the inosine monophosphate dehydrogenase (IMPDH) enzyme, which is critical for the de novo synthesis of guanosine nucleotides.

Lymphocyte Specificity: Unlike many other cells that can salvage purines, T and B lymphocytes depend almost exclusively on this de novo pathway for DNA synthesis and proliferation.
Immune Suppression: By blocking this pathway, MPA inhibits the proliferation of activated lymphocytes, reduces antibody formation, and suppresses cell-mediated immune responses.
Additional Effects: Research suggests it may also induce apoptosis in activated T-lymphocytes and decrease the expression of adhesion molecules, reducing the recruitment of inflammatory cells to sites of injury.

2. Clinical Indications

FDA-Approved Uses: Prophylaxis of acute organ rejection in adult and pediatric patients (3 months and older) receiving kidney, heart, or liver transplants.
Off-Label Uses (.org/.edu Evidence):
- Rheumatology: Lupus nephritis, systemic lupus erythematosus (SLE), rheumatoid arthritis, and various forms of vasculitis.
- Dermatology: Severe eczema, pemphigus vulgaris, bullous pemphigoid, and psoriasis.
- Other: Autoimmune hepatitis and inflammatory bowel disease (IBD).

3. Pharmacokinetics & Administration

Bioavailability: Rapidly absorbed after oral administration with high bioavailability (up to 94%).
Metabolism: MMF is an inactive prodrug hydrolyzed in the liver to the active metabolite, MPA.
Dosage Forms: Available as 250 mg capsules, 500 mg tablets, oral suspension, and intravenous (IV) infusion.
Standard Dosing: Typically administered twice daily (e.g., 1g twice daily for renal transplants).

4. Side Effects & Safety Warnings

Category	Common Side Effects	Serious Risks
Gastrointestinal	Nausea, vomiting, diarrhea, abdominal pain	GI bleeding or ulcers
Hematologic	Anemia, leukopenia (low white cells), thrombocytopenia	Bone marrow suppression
Infections	Increased risk of viral (CMV, BK virus), bacterial, and fungal infections	Fatal sepsis or opportunistic infections
Malignancy	Skin cancer risk (squamous cell carcinoma)	Increased risk of lymphoma

Black Box Warnings:

Pregnancy: High risk of miscarriage and severe congenital malformations (birth defects).
Infection & Lymphoma: Increased susceptibility to serious infections and certain cancers due to intense immunosuppression.
PML: Very rare but potentially fatal Progressive Multifocal Leukoencephalopathy (viral brain infection).